These results were similar to those reported in previous studies [6,7,8], showing that the overexpression of EGFR activated the Akt and ERK signaling pathway to increase HCC cell survival and proliferation, which, in turn, induced sorafenib resistance. The gene discussed is AKT1; the disease is hepatocellular carcinoma.